INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes

20254 citationsJournal Articlegreen Open Access

Authors

Michael J. Haller · University of Florida

Lauren Kanapka · Jaeb Center for Health Research

Roshanak Monzavi · Children's Hospital of Los Angeles

Thomas J. Mouse · Jaeb Center for Health Research

Gnanagurudasan Prakasam · Sutter Medical Center

Asheesh K. Dewan · Diabetes & Endocrinology Specialists

Linda A. DiMeglio

Abstract

The primary analysis did not meet the prespecified criteria for HbA1c noninferiority. However, TI use was safe over 26 weeks without affecting pulmonary function and was associated with greater treatment satisfaction and less weight gain compared with RAA, supporting TI as a treatment option for some pediatric patients with type 1 diabetes.

Topics & Keywords

Inhalation and Respiratory Drug Delivery Asthma and respiratory diseases Cystic Fibrosis Research Advances

Publication Details

Published in: Diabetes Care

Volume 49, Issue 1, pp. 179-187

DOI: 10.2337/dc25-1994

Field-Weighted Citation Impact: 6.24

Command Palette

INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes

Authors

Abstract

Topics & Keywords

Publication Details